文献速递肿瘤 PET/CT

非小细胞肺癌(NSCLC)中的「数字活检」:一项基于[18F]FDG PET/CT影像组学特征预测PD-L1状态的初步研究

The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-04-11

本研究为回顾性队列,纳入265例经活检证实的NSCLC患者中的86例有PD-L1免疫组化评估及[18F]FDG PET/CT扫描者,提取527个影像组学特征,探索其预测PD-L1表达状态的能力。结果显示SUVmax仅能区分强表达者(p=0.032),三个影像组学特征组合模型区分强表达者的敏感度81%、特异度82%,但预测PD-L1阳性(≥1%)能力有限。作者认为[18F]FDG PET影像组学可能有助于预测PD-L1强表达,这些初步数据需在更大或单扫描仪系列中确认。

要点

  • SUVmax在单变量分析中可区分PD-L1强表达者(p=0.032),但不能区分PD-L1阳性(≥1%)患者。
  • 三个影像组学特征组合的三变量线性判别模型区分PD-L1强表达者敏感度81%、特异度82%。
  • 影像组学预测PD-L1阳性(≥1%)患者的能力 scarce。

核心结论

  • 数据提示[18F]FDG PET影像组学在预测PD-L1强表达方面可能有作用。
  • 这些初步数据需在更大或单扫描仪系列中确认。

研究设计与样本

  • 回顾性队列研究,从265例经活检证实的NSCLC患者中选取86例有PD-L1免疫组化评估和[18F]FDG PET/CT扫描者。
  • 代谢参数从三台PET/CT扫描仪(Discovery 600、Discovery IQ和Discovery MI)提取,影像组学特征用符合IBSI的算法在原始图像及LLL和HHH coif1小波滤波图像上计算,每肿瘤获得527个特征。
  • 采用单变量和多变量分析比较PD-L1表达状态与所选影像组学特征。

主要发现

  • 86例中PD-L1免疫组化阴性46例(53%),低表达(1-49%)13例(15%),强表达(≥50%)27例(31%)。
  • SUVmax在单变量分析中区分强表达者有显著能力(p=0.032),但未能区分PD-L1阳性(PD-L1≥1%)患者。
  • 三个影像组学特征最能区分强表达者:代表球形VOI内平均高频病灶内容的特征(p=0.009);评估高频病灶内容上相邻体素间相关性的特征(p=0.004);强调病灶内存在相似灰度小区域的特征(p=0.003)。
  • 结合三个特征的三变量线性判别模型在测试中达到敏感度81%和特异度82%。
  • 影像组学预测PD-L1阳性患者的能力 scarce。

关键数值与推荐

  • PD-L1状态按肿瘤比例评分分为<1%、1-49%和≥50%,克隆号22C3。
  • 三变量线性判别模型区分PD-L1强表达者的敏感度81%、特异度82%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些初步数据需在更大或单扫描仪系列中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The present pilot study investigates the putative role of radiomics from [18F]FDG PET/CT scans to predict PD-L1 expression status in non-small cell lung cancer (NSCLC) patients. METHODS: In a retrospective cohort of 265 patients with biopsy-proven NSCLC, 86 with available PD-L1 immunohistochemical (IHC) assessment and [18F]FDG PET/CT scans have been selected to find putative metabolic markers that predict PD-L1 status (< 1%, 1-49%, and ≥ 50% as per tumor proportion score, clone 22C3). Metabolic parameters have been extracted from three different PET/CT scanners (Discovery 600, Discovery IQ, and Discovery MI) and radiomics features were computed with IBSI compliant algorithms on the original image and on images filtered with LLL and HHH coif1 wavelet, obtaining 527 features per tumor. Univariate and multivariate analysis have been performed to compare PD-L1 expression status and selected radiomic features. RESULTS: Of the 86 analyzed cases, 46 (53%) were negative for PD-L1 IHC, 13 (15%) showed low PD-L1 expression (1-49%), and 27 (31%) were strong expressors (≥ 50%). Maximum standardized uptake value (SUVmax) demonstrated a significant ability to discriminate strong expressor cases at univariate analysis (p = 0.032), but failed to discriminate PD-L1 positive patients (PD-L1 ≥ 1%). Three radiomics features appeared the ablest to discriminate strong expressors: (1) a feature representing the average high frequency lesion content in a spherical VOI (p = 0.009); (2) a feature assessing the correlation between adjacent voxels on the high frequency lesion content (p = 0.004); (3) a feature that emphasizes the presence of small zones with similar grey levels inside the lesion (p = 0.003). The tri-variate linear discriminant model combining the three features achieved a sensitivity of 81% and a specificity of 82% in the test. The ability of radiomics to predict PD-L1 positive patients was instead scarce. CONCLUSIONS: Our data indicate a possible role of the [18F]FDG PET radiomics in predicting strong PD-L1 expression; these preliminary data need to be confirmed on larger or single-scanner series.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Monaco L, De Bernardi E, Bono F, et al. The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2022. PMID: 35403860. doi:10.1007/s00259-022-05783-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。